On Tuesday (August 14), CannTrust Holdings (TSX:TRST) reported a 99-percent rise in revenue as part of its second-quarter results for 2018.

Sales for dried cannabis reached just over C$3.5 million for the three-month period, which ended on June 30, compared to a little under C$2 million for the same time period last year. Total revenues for the Canadian licensed producer were C$9 million for the second quarter.


During the quarter, CannTrust’s net selling price per gram lowered from last year to C$8.36.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Eric Paul, CEO of CannTrust, said the company was pleased with its results for the second quarter and is well positioned as a developer of cannabis products for the medical market.

The company revealed its earnings took a hit from C$1.5 million in costs for the ramp up of its Niagara Perpetual Harvest Facility, where expansion construction started in June.

According to the report, the company held a C$11.7-million position in cash as of June 30.

The president of the company, Brad Rogers, added that the operation of the company’s Perpetual Harvest Facility shows the ability for CannTrust to produce high-quality yields and reduced costs.

“Operating a facility of this scale, CannTrust is well-positioned to meet the increased Canadian and global demand for cannabis,” Rogers said.

The 450,000-square-foot hydroponic facility is expected to produce 50,000 kilograms of cannabis per year, before the completion of the 600,000-square-foot expansion. CannTrust estimates the final facility will produce over 100,000 kilograms of cannabis per year.

As part of its quarterly developments, the company highlighted that of the entirety of its cannabis sales, 60 percent represented extracts. The patient count for CannTrust also grew to over 45,000 active consumers of its products.

Investor takeaway

The company holds a “strong buy” rating on the analyst data aggregator site TipRanks, thanks to the reviews from three cannabis analysts.

The most recent report on CannTrust, from Derek Dlay with Canaccord Genuity, gives the company a C$11 share price target. The aggregate price target from TipRanks is C$15.50.

Following an early dip for the stock, shares for CannTrust rose 3.33 percent. The company’s closing price on Tuesday was C$6.83.

The increase for CannTrust represents strong support for its results, as Tuesday’s trading session brought declines across the board in the cannabis space due to Ontario’s decision to delay retail sales of cannabis until April 1, 2019.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less